This commentary explains why comparing a launch price with a value-based price from a cost-effectiveness analysis requires further examination.
Louis P. Garrison Jr, PhD
Advertisement
Articles by Louis P. Garrison Jr, PhD
Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
4
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
5